Biotech Co.* (Symbol)

Pharma Co. (Symbol/Country)

Type/Product Area

Disclosed Funding (M)

Terms/Details (Date)

3-Dimensional Pharmaceuticals Inc.*

DuPont Pharmaceuticals Co. (subsidiary of E.I. DuPont de Nemours & Co.; NYSE:DD)

Research collaboration/target discovery and use of 3-D's Directed Diversity technology to generate combinatorial chemistry libraries for drug discovery

$9

3-D will generate custom libraries and optimize them to obtain preclinical candidates; for the initial target, 3-D will receive up to $9M, including an up-front technology access fee, R&D funding and milestones; 3-D also will receive royalties on any sales and will be eligible to receive additional payments if more than one target is selected; additional agreement provides DuPont a non-exclusive license to Directed Diversity to support internal projects; DuPont will pay an annual site license fee for each facility using the technology (2/00)

Boehringer Ingelheim Pharmaceuticals Inc. (unit of Boehringer Ingelheim International GmbH; Germany)

Research collaboration/use of 3-D's Directed-Diversity combinatorial chemistry to discover and refine compounds active against BI targets

ND

3-D will receive an up-front technology access fee, R&D funding, milestones and royalties on each target selected; BI is responsible for preclinical and clinical development (3/00)

Alkermes Inc. (ALKS)

Ares-Serono

Research collaboration/development of extended-release version of an undisclosed AresSerono therapeutic protein

$30

Ares-Serono gains exclusive worldwide rights to products resulting from the collaboration, and will provide development funding, milestones that could exceed $30M, plus royalties based on sales; Alkermes is expected to manufacture products; Ares-Serono will handle clinical trials, approvals and marketing (1/00)

Glaxo Wellcome plc (UK; NYSE: GLX)

License agreement and research and development collaboration/use of Alkermes' AIR pulmonary drug delivery technology for multiple product candidates in respiratory diseases

ND

Glaxo receives exclusive worldwide rights to products in up to four undisclosed respiratory disease categories, and will provide development funding and milestones, as well as royalties on product sales; each company will have manufacturing rights and obligations; Glaxo is responsible for clinical trials, regulatory approvals and marketing (2/00)

Alkermes Inc. (ALKS)

Eli Lilly and Co. (NYSE:LLY)

License agreement and research and development collaboration/inhaled formulation of human growth hormone based on Alkermes' AIR pulmonary drug delivery system

ND

Agreement follows succesful completion of nine-month feasibility program conducted by the two companies; Alkermes will receive up-front fees, research funding and milestones, plus royalties on any sales; Lilly receives exclusive worldwide rights and will be responsible for clinical trials, regulatory approvals and marketing on a worldwide basis (2/00)

American Biogenetic Sciences Inc. (OTC BB:MABA)

Abbott Laboratories (NYSE:ABT)

License agreement/ABS' neurological compound ABS-103 (derivative of epilepsy drug valproate)

ND

Abbott gains exclusive worldwide rights to develop and market the compound, and will make an up-front equity investment as well as additional milestone payments (1/00)

AMRAD (Australia)

Ares-Serono Group (Switzerland)

License agreement and research collaboration/recombinant leukemia inhibitory factor for use in the field of reproductive health

$16

Ares-Serono made an undisclosed up-front payment and will pay milestones of up to $16M, plus royalties on any product sales; AMRAD is developing the protein for neuromuscular diseases under the name AM424 (1/00)

Arena Pharmaceuticals Inc.*

Fujisawa Pharmaceutical Co. Ltd. (Japan)

Research collaboration/validation of orphan G protein-coupled receptors as drug screening targets; use of Arena's CART technology to identify modulators of GPCRs in a ligand independent manner

ND

Companies will jointly validate selected GPCR targets; Arena will be responsible for receptor identification and regulation, application of its CART technology to Fujisawa-selected receptors and validation of screening assays based upon selected receptors; Fujisawa will screen its compound library using CART receptor assays and will handle preclinical and clinical development of leads; agreement includes an opportunity for Arena to screen selected receptors using its in-house library; Arena will receive assay license, milestone and potential royalty payments (1/00)

Argonex Inc.*

Wyeth-Lederle Vaccines (division of American Home Products Corp.; NYSE: AHP)

Research collaboration/identification of antigens associated with Chlamydia pneumoniae for development of potential vaccines

ND

Argonex will use its antigen technology to isolate, identify and sequence peptides uniquely expressed on cells infected with C. pneunomiae; Wyeth-Lederle will evaluate the peptides for potential use in vaccine development; Argonex will receive research funding and potential royalties (2/00)

Array BioPharma Inc.*

Asahi Chemical Industry Co. Ltd.

Research collaboration/access to Array's small-molecule libraries

ND

Asahi gains access to Array's libraries on a semi-exclusive basis (3/00)

Artemis Pharmaceuticals GmbH* (Germany)

Bayer AG (Germany)

Research collaboration/use of Artemis technology to develop methods for toxicology testing for pharmaceutical and crop protection compounds

ND

ND (2/00)

Axys Advanced Technologies Inc. (subsidiary of Axys Pharmaceuticals Inc.; AXPH)

Genomics Institute of the Novartis Research Foundation (unit of Novartis AG;Switzerland)

Research collaboration/use of small-molecule compounds created using Axys' combinatorial chemistry technologies

ND

The institute will screen the compounds to detect changes in gene expression; in addition the entities will develop novel chemistries together (1/00)

Bristol-Myers Squibb Co. (NYSE:BMY)

Research collaboration/use of Axys compounds for screening, plus transfer of technologies for reproducing and expanding the library

ND

Axys will receive payments for product delivery and technology transfer (2/00)

Avigen Inc. (AVGN)

BTG International Inc. (subsidiary of BTG plc; LSE: BGC)

License agreement/gene therapy using Factor IX for treatment of hemophilia B

ND

Avigen licensed rights to Factor IX for use in its gene therapy delivery system; Avigen will pay an up-front fee and milestones (3/00)

BioFocus plc* (UK)

Boehringer Ingelheim Pharmaceuticals Inc. (unit of Boehringer Ingelheim; Germany)

Research collaboration/compound design and synthesis, plus analysis of resulting biological screening data

ND

BioFocus will provide chemistry support and analysis of screening data (2/00)

Bioject Medical Technologies Inc. (BJCT)

Serono Laboratories Inc. (U.S. affiliate of the Ares-Serono Group; Switzerland)

License agreement/development of customized version of Bioject's needle-free delivery system to deliver Serono's Saizan recombinant human growth hormone

ND

Serono has U.S. and Canadian rights to use the system for its growth hormone, and will pay an undisclosed license fee; the companies signed a supply agreement that commences upon FDA clearance (1/00)

Bioreason Inc.*

Pharmacia & Upjohn (NYSE: PNU)

Evaluation agreement/use of Bioreason's suite of process improvements for screening

ND

P&U will evaluate the impact of Bioreason's technology and services on lead discovery and characterization (2/00)

Coley Pharmaceutical Group (formerly CpG ImmunoPharmaceuticals)

SmithKline Beecham (NYSE:SBH)

License agreement/development of immunotherapeutic products based on CpG DNA, including lead immune stimulant CpG 7909

$72

SmithKline gains a worldwide coexclusive license to CpG DNA-based compounds for use in certain therapeutic and prophylactic vaccines for infectious diseases; in exchange, Coley could receive up to $72M in license fees, research funding and milestones, including an $8M up-front payment (1/00)

CytRx Corp. (CYTR)

ND

Evaluation agreement/use of CytRx's gene delivery technology in a gene-based vaccine for HIV

ND

A "major pharmaceutical company" is evaluating the CytRx technology, and has an exclusive option to license the technology under terms to be negotiated; CytRx will provide material and consulting services during the evaluation period in exchange for certain payments (3/00)

Deltagen Inc.*

Merck & Co. Inc. (NYSE:MRK)

Research collaboration/production and analysis of knockout mice in order to characterize gene function

ND

Merck will provide target gene sequences, and Deltagen will produce and analyze knockout mice (2/00)

Schering-Plough Research Institute (unit of Schering-Plough Corp.; NYSE:SGP)

Research collaboration/validation of small-molecule drug targets using knockout mice, which aid in characterizing gene function

ND

Schering-Plough will provide target gene sequences, and Deltagen will produce and analyze knockout mice (2/00)

DGI BioTechnologies LLC*

Novo Nordisk A/S (Denmark; NYSE:NVO)

Expansion of 6/99 collaboration using DGI's Diogenesis drug lead discovery platform

ND

Updated agreement provides supplemental funding to support accelerated pace of research (3/00)

DoubleTwist Inc.*

Berlex Laboratories Inc. (unit of Schering AG; Germany)

License agreement/DoubleTwist's clustering and alignment tools for genomic data

ND

Berlex gains a non-exclusive license (2/00)

D-Pharm Ltd.* (Israel)

Shire Pharmaceuticals Group plc (LSE:SHP)

License agreement/D-Pharma's DP-VPA, a chemical analogue of valproic acid for the treatment of central nervous system disorders

ND

D-Pharm receives an up-front fee and equity investment, as well as milestones; D-Pharm retains manufacturing rights and intends to become sole supplier of bulk compound, which Shire will purchase at a price that includes a royalty rate; Shire will be responsible for development and regulatory activities (3/00)

Dynavax Technologies Corp.*

Aventis Pasteur (unit of Aventis SA; NYSE:AVE)

Research collaboration/development of new prophylactic and therapeutic vaccines for the diseases using Dynavax's immunostimulatory DNA sequences treatment of infectious

ND

Aventis Pasteur has the option to acquire exclusive worldwide rights to use ISS for specific disease targets in return for equity investments, research and development funding, milestones and royalties; Genavent, a venture capital fund of Societe Generale Asset Management and Aventis, will make an equity investment (2/00)

Elan Corp. plc (NYSE:ELN)

Wyeth-Ayerst Research (unit of American Home Products Corp.; NYSE:AHP)

Research, development and license agreement/small-molecule inhibitors of Elan's cell-adhesion molecule Alpha4-Beta2

ND

Companies collaborated in the integrin inhibitor field from 1991-97; under new agreement, Elan received an up-front payment and could receive additional fees and milestones, plus royalties; Elan may opt to co-promote products with Wyeth for a share of operating profits in lieu of royalty (1/00)

Electrofect*

Boehringer Ingelheim GmbH International (Germany)

License agreement/Electrofect's electroporation technology for DNA delivery in the field of oncology

ND

Non-exclusive license; further details ND (2/00)

Endorex Corp. (AMEX:DOR) and Elan Corp. plc (NYSE:ELN)

Schein Pharmaceutical Inc. (NYSE:SHP)

License, co-development and supply agreement/iron chelating products using Elan's Medipad drug delivery system for treatment of certain genetic blood disorders resulting from iron overload

ND

Schein receives an exclusive worldwide sublicense to utilize Medipad for delivery of a Schein iron chelator; in the U.S., the groups will develop a drug/device product as part of a clinical testing program; Schein has U.S. marketing products and the companies together will identify sublicensees for international markets (2/00)

Endorex Corp. (AMEX:DOR)

Novo Nordisk A/S (Denmark; NYSE:NVO)

Research and option agreement/formulation >of Novo's Norditropin brand of human growth hormone using Endorex's Orasome oral delivery system

ND

Novo has exclusive worldwide rights to license the Orasome system for Norditropin; companies will further evaluate product in animal models (3/00)

EpiGenesis Pharmaceuticals Inc.*

Chisei Faramaceutici SpA (Italy)

License and development agreement/EpiGenesis' EPI-2010, an antisense oligonucleotide for treatment of respiratory diseases

ND

EpiGenesis will receive development payments, as well as milestone fees and royalties on sales; Chisei will receive semi-exclusive marketing rights for the product and its use in asthma for Europe and other countries where Chisei has a presence; agreement includes possibility of a future collaboration for additional indications (1/00)

Gene Logic Inc. (GLGC)

Pfizer Inc. (NYSE:PFE)

Database subscription/access to Gene Logic's GeneExpress database of gene expression information for predictive toxicology applications

ND

Pfizer gains access to the database and will pay annual subscription fees (2/00)

Genset SA (France; GENXY)

Abbott Laboratories (NYSE:ABT)

Research collaboration/discovery of genes associated with bipolar disorder and Type II diabetes

ND

Abbott will receive a license to develop and commercialize therapeutic and diagnostic products based on genes identified through the collaboration; Genset will receive an up-front payment, research funding, milestones and royalties; Genset may exercise a put option to issue $10M worth of equity to Abbott (3/00)

Idun Pharmaceuticals*

Becton, Dickinson and Co. (NYSE: BDX)

License agreement/apoptosis reagents for use in the research market

ND

BD is exclusive licensee of Idun's apoptosis research reagents, and has the right to grant sublicenses; Idun receives an up-front payment, as well as royalties on sales (1/00)

IGI Inc. (AMEX:IG)

Fujisawa Pharmaceutical Co. Ltd. (Japan)

Development agreement/use of IGI's Novasome microencapsulation technology to develop a topical delivery system for a Fujisawa dermatological compound

ND

IGI will develop new formulation of undisclosed compound and will receive an up-front technology payment and potential milestones (1/00)

ImClone Systems Inc. (IMCL)

SmithKline Beecham plc (NYSE:SBH)

License agreement/proprietary antigens and related intellectual property owned by ImClone for inclusion in a vaccine against meningitis

ND

ImClone will receive an up-front fee and payments upon the achievement by SmithKline of certain clinical and regulatory milestones, plus royalties on sales (2/00)

Insmed Pharmaceuticals Inc.*

Taisho Pharmaceutical Co. Ltd. (Japan)

Letter of intent for development and commercialization rights/INS-1, a low-molecular-weight oral drug for polycystic ovary syndrome and Type II diabetes

ND

Taisho signed a letter of intent for rights to Insmed's INS-1 in Japan and other Asian countries; Taisho will pay up-front, development, milestone and royalty payments pursuant to a definitive agreement to be negotiated; in addition, Taisho will invest several million dollars in Insmed equity (3/00)

Isis Pharmaceuticals (ISIP)

AstraZeneca plc (UK; NYSE:AZN)

Research collaboration/use of Isis' antisense technology to assess and prioritize genes identified within Astra-Zeneca's genomics programs

ND

Isis will create antisense inhibitors to target genes in order to gather functional information (1/00)

Lexicon Genetics Inc.*

Roche Bioscience (unit of Roche Holding Ltd.; Switzerland)

Sublicense agreement/use of certain aspects of Lexicon's positive-negative selection and isogenic DNA technology to improve efficiency of genes targeted in knockout mice

ND

Roche will use the technology for its internal programs (1/00)

Lexicon Genetics Inc.*

R.W. Johnson Pharmaceutical Research Institute (unit of Johnson & Johnson; (NYSE:JNJ)

Research collaboration/access to Lexicon's knockout mouse technology, and to its Seek Target Validation program to determine the function and pharmaceutical relevance of genes by analyzing knockout mice

ND

Multi-year agreement; details ND (1/00)

Searle (pharmaceutical division of Monsanto Co.; NYSE:MTC)

Research collaboration/access to Lexicon's knockout mouse technology

ND

Multi-year agreement under whichSearle will pay annual access and project fees with minimum annual commitments (1/00)

Boehringer Ingelheim Pharmaceuticals Inc. (unit of Boehringer Ingelheim GmbH International; Germany)

Research collaboration/Internet access to Lexicon's gene sequence database and library of knockout mouse clones for use in determining the function of genes that represent potential gene targets

ND

Multi-year agreement under which BI will have non-exclusive access to Lexicon's OmniBank database in exchange for annual access fees; Lexicon also may receive royalties on sales of products developed using genes discovered using the database; BI also will have access to knockout mice in exchange for agreed-upon fees with minimum annual commitments (2/00)

Lexicon Genetics Inc.*

NV Organon (the Netherlands)

Research collaboration/access to Lexicon's knockout mouse technology

ND

Multi-year agreement under which Organon will pay annual access and project fees with minimum annual commitments (2/00)

LifeSpan BioSciences Inc.*

Pfizer Inc. (NYSE:PFE)

Database subscription/database of information on the expression and localization of G protein-coupled receptors

ND

Pfizer receives early access to localization data on GPCR targets, which will be added continuously to the database over a two-year period (3/00)

Life Technologies Inc. (OTC BB:LTEK)

Amgen Inc. (AMGN)

Research collaboration/use of Life's full-length cDNA library technology to complement Amgen's gene discovery efforts

ND

Terms call for a payment for each full-length cDNA library constructed, as well as payments for each full-length clone selected by Amgen for discovery research (2/00)

Ligand Pharmaceuticals Inc. (LGND)

NV Organon (The Netherlands)

Research collaboration/discovery and development of small-molecule compounds for treating and preventing gynecological diseases mediated through the progesterone receptor

ND

Ligand received undisclosed up-front payments for research reimbursements and may receive milestones and royalties; Organon gains exclusive worldwide rights to manufacture and sell any resulting products (2/00)

Inpharmatica* (UK)

Parke-Davis (division of Warner-Lambert Co.; NYSE:WLA)

Bioinformatics access/Inpharmatica's Biopendium platform for identifying, prioritizing and validating drug targets

ND

Parke-Davis signed a three-year, multimillion dollar agreement to become the first partner to gain access to Biopendium; Parke-Davis has an option to expand and extend the collaboration (1/00)

Medarex Inc. (MEDX)

Kirin Brewery Co. Ltd. (Japan)

Cross-licensing agreement and research collaboration/mouse technology for creating monoclonal antibodies (Medarex's HuMAb Mouse and Kirin's Transchromosomic Mouse)

$12M

Kirin will pay a $12M up-front fee for exclusive rights to distribute the technology in Asia; Medarex gains exclusive distrbution rights to Kirin's mouse technology outside of Asia; companies will exchange broad licenses, subject to milestones and royalties, for in-house use of each other's technology for the development of antibody therapeutics; companies will initiate a research collaboration to create a novel approach for the development of fully human antibodies by combining their technologies; alliance could generate third-party milestones of more than $250M (1/00)

MediGene AG (Germany)

Aventis Pharma AG (unit of Aventis SA; NYSE:AVE)

Research collaboration/Medigene's gene therapy tumor vaccine using recombinant adenoassociated viruses for treatment of malignant melanoma

$34M

Aventis gains an exclusive license to develop and commercialize the vaccine in 37 countries (including the European Union, North America and Japan) with rights to grant sublicenses; total deal value could amount to $34M, including up-front fees, milestones and R&D funding; in addition, MediGene will receive royalties on sales and promotion rights for most Eastern European countries and a number of South American, Far East and Middle East countries; Aventis will be responsible for manufacturing GMP material and will handle Phase III trials and regulatory matters (2/00)

Millennium Pharmaceuticals Inc. (MLNM)

Taisho Pharmaceutical Co. Ltd. (Japan)

License agreement/Millennium's LDP-977 for the treatment of chronic asthma

ND

Companies signed a letter of intent granting Taisho an exclusive license in Japan, Asia and Europe; Taisho will fund all research and development expenses in Japan and Asia, and two-thirds of the expenses in the U.S. and Europe; Taisho also will pay a licensing fee, plus milestones based on progress in its territories; Millennium will manufacture the product for Taisho and receive supply fees based on sales; Taisho has the right of first negotiation for commercialization in the U.S. should Millennium seek to sublicense in that territory (1/00)

Myriad Genetics Inc. (MYGN)

Hoffmann-La Roche Inc. (Switzerland)

Research collaboration/use of Myriad's ProNet to discover drug targets for treating heart disease

$13

Myriad will receive up to $13M in research funding, license fees and milestones, plus royalties on any sales (1/00)

Neurocrine Biosciences Inc. (NBIX)

Taisho Pharmaceutical Co. Ltd. (Japan)

Licensing option/Neurocrine's altered peptide ligand (NBI-6024) for diabetes

$45

Taisho gains an exclusive option to license rights for Europe and Asia; approximate value of the collaboration is $45M, which includes licensing and option fees, milestones and reimbursement of 50% of worldwide development expenses; in addition, Neurocrine will receive royalties on sales in Taisho's territories (1/00)

NeuroSearch A/S (Denmark; Copenhagen: NEUS.CO)

Abbott Laboratories (NYSE:ABT)

Research collaboration/use of NeuroSearch's drug discovery platform for a family of ion channels to discover compounds for treatment of a variety of central and peripheral nervous system disorders

$17

Abbott gains exclusive worldwide rights to compounds discovered in the collaboration; Abbott will finance all R&D doneby both project partners, and will pay up to $17M in milestones for each successfully developed compound, as well as royalties on sales (1/00)

Glaxo Wellcomeplc (UK; NYSE: GLX)

Development agreement/NeuroSearch's antidepressant, NS2389

$57

NeuroSearch will receive a first-phase payment of $10M, additional premarketing milestones of up to $47M and royalties on any sales (1/00)

Oceanix Biosciences Corp.*

Glaxo Wellcome plc (UK; NYSE: GLX)

Research collaboration and database access/Oceanix's Receptor Selectivity Mapping Database, which contains data on interactions between compounds and disease-related targets

ND

Glaxo gains non-exclusive access to the database for internal use in drug discovery and development; Glaxo will provide slected compounds to Oceanixto be screened against a range of molecular targets and included in the database and shared between Oceanix and Glaxo; agreement could encompass joint development of data mining tools; Glaxo will pay access and screening fees (2/00)

OSI Pharmaceuticals Inc. (OSIP)

R.W. Johnson Pharmaceutical Research Institute (unit of Johnson & Johnson; NYSE:JNJ)

License agreement/OSI's gene transcription patent estate

ND

OSI will receive annual fees, together with milestones and success payments from small-molecule gene transcription modulators developed and marketed; license is non-exclusive (1/00)

American Home Products Corp. (NYSE:AHP)

Cross-licensing agreement/OSI's gene transcription patent estate and a family of patents covering yeast screening technologies developed by AHP subsidiary American Cyanamid

ND

OSI gains access to American Cyanamid technology, including claims for recombinant expression of a variety of targets in yeast, including G protein-coupled receptors; cross-license allows American Cyanamid to retain exclusive rights to use the GPCR technologies in the agricultural field (1/00)

Oxford BioMedica plc (LSE:OXB)

AstraZeneca plc (UK;NYSE:AZN)

Research collaboration/use of Oxford's LentiVector gene delivery technology to deliver genes that are central to a number of disease processes, including asthma

ND

ND (2/00)

Oxford GlycoSciences plc (LSE:OGS)

Bayer AG (Germany)

Research collaboration/use of OGS' proteomicstechnology to identify disease-associated proteins as potential targets for drug discovery

ND

Bayer has committed funding for an initial term of two years and will pay milestones and royalties; parties will jointly own any intellectual property arising from collaboration, and OGS will have exclusive rights to commercialize diagnostic markers identified (3/00)

Pharmacopeia Inc. (PCOP)

NV Organon (The Netherlands)

Research collaboration/small-molecule antagonists of interleukin-8 for treating inflammatory

ND

Pharmacopeia will receive research funding to pursue further chemical optimization of lead compounds already identified by Pharmacopeia; Organon will handle development and commercialization of lead compound (1/00)

Phase-1 Molecular Toxicology Inc.*

PE Biosystems Group (NYSE: PEB)

Development collaboration/high-throughput gene expression assays for preclinical drug toxicity evaluations

ND

Phase-1 and PE will share technical responsibility for the development and validation of a panel of approximately 50 gene expression assays; Phase-1 will choose the target genes and validate the assays for the targets; PE will design, develop, manufacture and market the assays; Phase-1 also will develop positive controls (full-length cDNA clones) to test specificity of the assays; PE will market those controls; during the final stage of the project, Phase-1 will create a database of the gene expression profiles for the targeted genes for cDNA samples from rat and human cells exposed to 50 reference compounds; reagents for this panel will be made available in an ABI PRISM card format (3/00)

Protein Design Labs Inc. (PDLI)

Fujisawa Pharmaceutical Co. Ltd. (Japan)

Research collaboration/use of PDL's humanization technology for an antibody to treat inflammatory and immunologically mediated diseases

$1.5

Fujisawa will pay a $1.5M signing fee, plus milestones, annual maintenance fees and royalties on any product sales (2/00)

Quantum Dot Corp.*

Genomics Institute of the Novartis Research Foundation (unit of Novartis AG; Switzerland)

Research collaboration/use of Quantum Dot's nanocrystals to develop biological assays for proteome analysis and gene expression

ND

ND (3/00)

Quark Biotech Inc.*

Shionogi & Co. (Japan)

License agreement and research collaboration/use of Quark's technology to discover and analyze genes associated with osteoarthritis

ND

Quark will identify and characterize genes; Shionogi will develop and manufacture pharmaceutical and diagnostic candidates resulting from the genes and will have exclusive marketing rights in the Far East; companies will share marketing rights elsewhere (1/00)

Sangamo BioSciences Inc.*

Baxter Healthcare Corp. (U.S. subsidiary of Baxter International Inc.; NYSE:BAX)

Research collaboration/development and commercialization of therapeutics for ischemic cardiovascular and peripheral vascular diseases using Sangamo's zinc finger DNA binding proteins (ZFPs) for activation of vascular endothelial growth factor

$40

Sangamo may receive up to $40M in research funding, option fees, loans and milestones, and also will receive royalties on any sales; Sangamo will design and advance products through preclinical testing, and Baxter will be responsible for production, clinical trials, approvals and marketing; Baxter also gains a three-year right of first refusal to Sangamo's ZFP cardiovascular product candidates (1/00)

Procter & Gamble Pharmaceuticals (unit of Procter & Gamble; NYSE: PG)

Research collaboration/use of Sangamo's Universal GeneTools

ND

Sangamo will provide specific Universal GeneTools to P&G for internal research and validation (3/00)

SkyePharma plc (SKYE)

Pfizer Inc. (NYSE:PFE)

Feasibility contract/use of SkyePharma's Geomatrix oral delivery technology to formulate a Pfizer compound

ND

ND (3/00)

Synaptic Pharmaceutical Corp. (SNAP)

Kissei Pharmaceutical Co. Ltd. (Japan)

License agreement and research collaboration/identification and development of drugs that act through receptors which will be identified using Synaptic's genomics technologies

ND

Synaptic will receive a license fee, research funding, milestones and royalties on any drug that emerges from the program; Kissei will have worldwide exclusive rights to use selected receptors from the collaboration to develop, manufacture and market associated drugs (1/00)

Synsorb Biotech Inc. (Canada; SYBB)

BCY Ventures Inc. (CDNX: BCY)

License agreement/Synsorb's technologies relating to treatment of complications associated with cystic

ND

BCY will issue up to 1.6M common shares to Synsorb, which will represent 30% of all shares of BCY on a fully diluted basis; BCY will issue 0.8M shares upon closing of the the transaction and an additional 0.8M shares upon achievement of milestones; Synsorb will act as a resource to BCY in developing the technologies (2/00)

Titan Pharmaceuticals Inc. (AMEX:TTP)

Schering AG (Germany)

Development, manufacturing and commercialization agreement/Titan's cell therapy for the treatment of Parkinson's disease

ND

Titan and Schering will collaborate on the manufacturing and clinical development of product; Titan will receive funding for development activities, as well as reimbursement for some prior R&D expenses; Schering will fully fund, and manage in collaboration with Titan, all future clinical trials; Schering receives exclusive worldwide development, manufacturing and commercialization rights, and will pay royalties on any sales; Schering also has the right to make an equity investment in Titan upon initiation of pivotal clinical trials (2/00)

Tripos Inc. (TRPS)

Parke-Davis (division of Warner-Lambert Co.; NYSE:WLA)

Research collaboration/development of new informatics methods for high-throughput screening

ND

Three-year, multimillion dollar agreement under which Tripos and Parke-Davis will jointly design, develop and test screening analysis tools; results of the collaboration eventually will be made available as commercial software products (1/00)

Vion Pharmaceuticals Inc. (VION) and EPTTCO Ltd.* (UK)

AstraZeneca plc (UK; NYSE:AZN)

Option agreement/anticancer therapies incorporating Vion's TAPET bacterial vector armed with EPTTCO's prodrug activation technology, which uses enzymes to convert inactive prodrugs into cytotoxics

ND

AstraZeneca will evaluate products over nine months; Vion and EPTTCO will handle preclinical testing and AstraZeneca will provide access under its rights to certain prodrugs; AstraZeneca has an exclusive option period to license the specific EPTTCO-armed TAPET vector; Vion and EPTTCO will receive option fees (1/00)

Xenometrix Inc. (OTC BB:XENO)

Pfizer Inc. (NYSE:PFE)

License agreement/Xenometrix's Yeast DEL technology for measuring genotoxic potential of compouds

ND

Pfizer will incorporate Xenometrix's genotoxicology methods into its screening process (3/00)

Notes:

# This chart contains information on new agreements, covering the time between 1/1/00 and 3/15/00. It does not include arrangements that are classified strictly as production, manufacturing, marketing and/or distribution and supply agreements; a chart covering these arrangements will appear in the 4/3/00 issue of BioWorld Financial Watch. The chart above also does not include any collaborations that involve agricultural product development (which are covered periodically in this publication).

Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 20-21.

AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; NM = Nouveau Marche; OTC BB = Over The Counter Bulletin Board

ND = Not disclosed, reported and/or available

* Private companies are indicated with an asterisk.

No Comments